Biotech Stock News (ATHX) (FLXN)

Athersys (NASDAQ:ATHX) In after-hours trade on February 18, 2016 shares of Athersys were up 21% after the company announced that it had obtained positive phase 2 results for its stroke trial. The phase 2 trial was broken down into two different parts. The first part was a dose selection phase of 16 patients split into … Read more

Biotech Stock News (AMPE) (ALNY) (AERI)

Ampio Pharmaceuticals (NASDAQ:AMPE) On April 20, 2015 Shares of Ampio Pharmaceuticals fell about 66% after the company reported that it had failed to meet the primary endpoint of a phase 3 clinical trial, known as the STRIDE trial. This trial recruited 320 patients with Osteoarthritis and patients were randomized into two different groups. One group … Read more